# OnCo record jupiter-02 (trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/trials/jupiter-02/>
  a schema:MedicalTrial ;
  onco:kind "trial" ;
  schema:identifier "jupiter-02", "NCT03581786" ;
  schema:name "JUPITER-02"@en ;
  schema:description "Brought immunotherapy to nasopharyngeal cancer, an Epstein-Barr-virus-driven cancer common in southern China, and won the first US approval for that disease."@en ;
  schema:url <https://onco.cc/trials/jupiter-02/> ;
  schema:dateModified "2026-09-07"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/study/NCT03581786>, <https://www.onclive.com/view/toripalimab-plus-chemo-maintains-survival-benefit-after-6-years-in-recurrent-metastatic-npc> ;
  onco:status "positive" ;
  onco:phase "3" ;
  schema:startDate "2018-10-18" ;
  onco:cancers <https://onco.cc/cancers/head-and-neck/>, <https://onco.cc/cancers/nasopharyngeal/>, <https://onco.cc/cancers/recurrent-metastatic-nasopharyngeal-carcinoma/> ;
  onco:technologies <https://onco.cc/technologies/checkpoint-inhibitor/> ;
  onco:targets <https://onco.cc/targets/pd1/> ;
  onco:drugs <https://onco.cc/drugs/toripalimab/> ;
  onco:companies <https://onco.cc/companies/junshi/>, <https://onco.cc/companies/coherus/> ;
  onco:institutions <https://onco.cc/institutions/sysucc/> ;
  onco:trials <https://onco.cc/trials/captain-1st/> ;
  onco:people <https://onco.cc/people/ma-jun/> .